866599-76-0

Upstream product

• 1428648-25-2 C₁₆H₁₃ClN₂O₃ 
• 866601-49-2 C₂₂H₁₉N₃O₃ 
• 1428648-00-3 C₁₆H₁₄N₂O₄ 
• 1422432-77-6 C₂₀H₂₂N₂O₄ 
• 75629-56-0 C₁₇H₂₁N₂O₂⁽¹⁺⁾*Br^(1-) 
• 75629-45-7 (Z)-3-(pyrrolidin-1-ylmethylene)-3H-indole 
• 487-89-8 Indole-3-carboxaldehyde 
• 332945-75-2 ethyl [3-(2-cyano-2-phenylcarbamoyl-vinyl)-indol-1-yl]-acetate 

Relevant academic research and scientific papers

Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold

(E)-2-(3-(3-((3-Bromophenyl)amino)-2-cyano-3-oxoprop-1-en-1-yl) -1H-indol-1-yl)acetic acid (1) was discovered in a HTS campaign for CRTh2 receptor antagonists. An SAR around this hit could be established and representatives with interesting activity profiles were obtained. Ring closing tactics to convert this hit series into a novel 2,3,4,5-tetrahydro-1H-pyrido[4, 3-b]indole based CRTh2 receptor antagonist series is presented.

INDOL-1-YL-ACETIC ACID DERIVATIVES

The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.